ID: ALA3747586

Max Phase: Preclinical

Molecular Formula: C19H23N3O

Molecular Weight: 309.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NC(=O)c2cc(N)ccc2N2CCCCC2)cc1

Standard InChI:  InChI=1S/C19H23N3O/c1-14-5-8-16(9-6-14)21-19(23)17-13-15(20)7-10-18(17)22-11-3-2-4-12-22/h5-10,13H,2-4,11-12,20H2,1H3,(H,21,23)

Standard InChI Key:  AQNGSUGPKOWLJF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 309.41

Molecular Weight (Monoisotopic): 309.1841

AlogP: 3.82

#Rotatable Bonds: 3

Polar Surface Area: 58.36

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.10

CX LogP: 3.71

CX LogD: 3.69

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.85

Np Likeness Score: -1.51

References

1. Caraballo R, Larsson M, Nilsson SK, Ericsson M, Qian W, Nguyen Tran NP, Kindahl T, Svensson R, Saar V, Artursson P, Olivecrona G, Enquist PA, Elofsson M..  (2015)  Structure-activity relationships for lipoprotein lipase agonists that lower plasma triglycerides in vivo.,  103  [PMID:26355531] [10.1016/j.ejmech.2015.08.058]

Source

Source(1):

• Scientific Literature